Xdemics has filed a notice of an exempt offering of securities to raise $7,639,835.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Xdemics is raising up to $7,639,835.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Xdemics
Advanced cell and gene therapies remain expensive and hard to make, impeding powerful treatment options for patients across the spectrum of human disease. XDemics, a venture-backed spin out from Caltech, tackles this challenge with a patented new technology that allows for the production of cell and viral-based therapeutics in a natural and efficient way. We achieved this by separating the supply of oxygen and nutrients, creating the perfect environment for cells to thrive in a scaleable, controllable and high quality manner. Our laboratory facilities are located on the beautiful campus of the world-famous Buck Institute in Marin County, California.
To learn more about Xdemics, visit http://xdemics.com/
Xdemics Linkedin Page: https://www.linkedin.com/company/xdemics-corporation/
Contact:
Christopher Thanos, Chief Executive Officer
415-637-6691
https://www.linkedin.com/in/christopher-thanos-35972a37/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.